Drug Profile
Research programme: angiogenesis inhibitors - ElexoPharm/PharmBioTec/Saarland University/SomantiX/VU University
Alternative Names: Small Mol Act; Tumour vessel targeting program - ElexoPharm/PharmBioTec/Saarland University/SomantiX/VU UniversityLatest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator ElexoPharm GmbH; Saarland University; SomantiX; VU University Medical Center
- Class Small molecules
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for research development in Colorectal-cancer in Germany
- 28 Feb 2018 No recent reports of development identified for research development in Colorectal-cancer in Netherlands
- 07 Nov 2011 Investigation in Colorectal cancer in Germany (unspecified route)